Unique Treatment for Ocular Redness Now Available Over-the-Counter

Lumify is the first OTC eye drop to contain low-dose brimonidine, an alpha-2 adrenergic receptor agonist
Lumify is the first OTC eye drop to contain low-dose brimonidine, an alpha-2 adrenergic receptor agonist

Bausch + Lomb announced the availability of Lumify (brimonidine tartrate ophthalmic solution) 0.025%, an over-the-counter (OTC) eye drop indicated to treat ocular redness. 

Lumify is the first OTC eye drop to contain low-dose brimonidine, an alpha-2 adrenergic receptor agonist that works by selectively constricting the veins in the eye, increasing the availability of oxygen to surrounding tissue and reducing the likelihood of rebound redness, often associated with non-selective redness relievers.

In clinical studies, Lumify eye drops showed a 95% improvement at 1 minute with sustained effects lasting up to 8 hours. Results from an in-home-use study (N>300) also showed a 95% satisfaction rating with Lumify. In total, 6 clinical studies were performed in over 600 patients to evaluate its safety and efficacy. A low risk of allergic reactions was observed for all patient groups. 

Related Articles

Lumify is available as a 0.025% strength solution in 2.5mL and 7.5mL bottles at major retailers.

For more information call (800) 553-5340 or visit LumifyEyeDrops.com.